MA27667A1 - Analogues de la prostaglandine comme antagonistes du recepteur de ep4 - Google Patents

Analogues de la prostaglandine comme antagonistes du recepteur de ep4

Info

Publication number
MA27667A1
MA27667A1 MA28497A MA28497A MA27667A1 MA 27667 A1 MA27667 A1 MA 27667A1 MA 28497 A MA28497 A MA 28497A MA 28497 A MA28497 A MA 28497A MA 27667 A1 MA27667 A1 MA 27667A1
Authority
MA
Morocco
Prior art keywords
receptor antagonists
prostaglandin analogs
prostaglandin
analogs
glaucoma
Prior art date
Application number
MA28497A
Other languages
English (en)
Inventor
Xavier Billot
John Colucci
Yongxin Han
Marie-Claire Wilson
Robert N Young
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of MA27667A1 publication Critical patent/MA27667A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

AGONISTE DU RECEPTEUR EP4, COMPOSITIONS ET METHODES POUR CELLES-LA Cette invention concerne des agonistes sélectifs puissants du sous-type EP4 des récepteurs E2 de la prostaglandine, leur usage ou une composition de ceux-là dans le traitement du glaucome et autres affections, qui sont liées à une pression intraoculaire élevée dans l'oeil d'un patient.
MA28497A 2003-03-26 2005-09-14 Analogues de la prostaglandine comme antagonistes du recepteur de ep4 MA27667A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45770003P 2003-03-26 2003-03-26

Publications (1)

Publication Number Publication Date
MA27667A1 true MA27667A1 (fr) 2005-12-01

Family

ID=33098243

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28497A MA27667A1 (fr) 2003-03-26 2005-09-14 Analogues de la prostaglandine comme antagonistes du recepteur de ep4

Country Status (22)

Country Link
US (4) US7053085B2 (fr)
EP (1) EP1613621B1 (fr)
JP (1) JP4866992B2 (fr)
KR (1) KR20060002873A (fr)
CN (1) CN1764659A (fr)
AR (1) AR040806A1 (fr)
AT (1) ATE474837T1 (fr)
BR (1) BRPI0408690A (fr)
CA (1) CA2519938C (fr)
CL (1) CL2004000655A1 (fr)
DE (1) DE602004028229D1 (fr)
EC (1) ECSP056037A (fr)
ES (1) ES2347434T3 (fr)
HR (1) HRP20050845A2 (fr)
IS (1) IS7999A (fr)
MA (1) MA27667A1 (fr)
MX (1) MXPA05010189A (fr)
NO (1) NO20054951L (fr)
PE (1) PE20050522A1 (fr)
RU (1) RU2005132930A (fr)
TW (1) TW200427670A (fr)
WO (2) WO2004085431A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CA2511255C (fr) * 2003-01-10 2009-04-07 F. Hoffmann-La Roche Ag Derives de 2-piperidone agonistes de la prostaglandine
US6977260B2 (en) 2004-01-22 2005-12-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7326716B2 (en) 2003-06-06 2008-02-05 Allergan, Inc. Treatment of inflammatory bowel disease
BRPI0411057A (pt) * 2003-06-06 2006-07-25 Allergan Inc análogos de prostaglandina e de piperidinila
US7179820B2 (en) 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
AU2004268012B2 (en) 2003-09-02 2008-11-20 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
DE602004020079D1 (de) 2003-09-04 2009-04-30 Merck & Co Inc Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
AU2004271978B2 (en) 2003-09-04 2009-02-05 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US7427614B2 (en) 2004-07-02 2008-09-23 Allergan, Inc. Prostaglandin analogs
CN1988903A (zh) * 2004-07-20 2007-06-27 默克公司 用于治疗高眼压症的眼用组合物
AU2005299473B2 (en) * 2004-10-26 2012-06-28 Allergan, Inc. Therapeutic and delivery methods of prostaglandin EP4 agonists
US7994195B2 (en) * 2004-11-04 2011-08-09 Allergan, Inc. Therapeutic substituted piperidone compounds
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
CN101133037B (zh) * 2005-01-27 2012-05-09 旭化成制药株式会社 六元杂环化合物及其用途
AU2006275270A1 (en) * 2005-08-03 2007-02-08 Merck Frosst Canada Ltd EP4 receptor agonist, compositions and methods thereof
US20090270395A1 (en) * 2005-08-03 2009-10-29 John Colucci EP4 Receptor Agonist, Compositions and Methods Thereof
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
US7498447B2 (en) 2006-05-24 2009-03-03 Allergan, Inc. Therapeutic compounds
US7550448B2 (en) 2006-05-24 2009-06-23 Allergan, Inc. Therapeutic compounds
WO2008027341A2 (fr) * 2006-08-30 2008-03-06 Merck & Co., Inc. Formulations ophtalmiques locales
WO2008027340A2 (fr) * 2006-08-30 2008-03-06 Merck & Co., Inc. Formulations ophtalmiques locales
EP2679221B1 (fr) 2006-10-20 2020-09-23 Children's Medical Center Corporation Procédé pour améliorer la régénération tissulaire
CN101168514B (zh) * 2006-10-26 2011-12-07 上海药明康德新药开发有限公司 光学活性α-氨基辛二酸酯和α-氨基辛二酸单酯的合成方法
US20080167377A1 (en) 2006-12-15 2008-07-10 Alessandra Gaiba Novel compounds
GB2446652A (en) * 2007-02-16 2008-08-20 Inion Ltd Osteogenic compounds
EP2147672A4 (fr) 2007-05-08 2011-11-02 Nat University Corp Hamamatsu University School Of Medicine Activateur de cellule t cytotoxique comprenant un agoniste ep4
CN101679262A (zh) * 2007-06-07 2010-03-24 安斯泰来制药株式会社 吡啶酮化合物
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
CN101468985A (zh) * 2007-12-28 2009-07-01 中国人民解放军军事医学科学院毒物药物研究所 5-(3-芳杂环取代苯基)四氮唑类化合物及其抗hiv/aids的应用
US8633310B2 (en) * 2008-02-19 2014-01-21 Allergan, Inc. Therapeutic substituted lactams
US7964596B2 (en) 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
WO2011047048A1 (fr) 2009-10-14 2011-04-21 Gemmus Pharma, Inc. Traitement par polythérapie pour infections virales
CA2738045C (fr) * 2010-05-28 2019-02-19 Simon Fraser University Composes conjugues, leurs procedes de fabrication et leurs utilisations
KR102456567B1 (ko) 2013-08-09 2022-10-19 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
CN107849072B (zh) 2015-06-12 2020-12-15 西蒙弗雷泽大学 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
WO2017126635A1 (fr) * 2016-01-22 2017-07-27 武田薬品工業株式会社 Composé hétérocyclique et utilisation de celui-ci
PT3733665T (pt) 2017-12-25 2022-10-21 Asahi Kasei Pharma Corp Compostos contendo unidade de 2-oxo-1,3,4-tiadiazinan-3-ilo com atividade agonista do recetor ep4
WO2020237096A1 (fr) 2019-05-21 2020-11-26 Ardelyx, Inc. Combinaison pour baisser le phosphate sérique chez un patient
CN111269193B (zh) * 2020-04-02 2022-05-24 湖南海利常德农药化工有限公司 一种苯并[e][1,3]噁嗪-2,4-二酮的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524818A (en) 1974-11-29 1978-09-13 Beecham Group Ltd 12-azaprostaglandins
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
EP0008186A1 (fr) 1978-08-08 1980-02-20 Beecham Group Plc Diamides cycliques, procédé pour leur préparation et leurs compositions pharmaceutiques
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) * 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
US4960771A (en) * 1988-07-12 1990-10-02 Rajadhyaksha Vithal J Oxazolidinone penetration enhancing compounds
DE1300150T1 (de) * 1988-09-06 2003-09-18 Pharmacia Ab, Stockholm Prostaglandin-Derivate zur Behandlung von Glaukom oder Augenüberdruck
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH10265454A (ja) 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
US6043275A (en) * 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
KR20010074981A (ko) 1998-09-14 2001-08-09 우에노 도시오 ω치환된 페닐프로스타그란딘 Ｅ 유도체 및 그 유도체를유효 성분으로 하는 약제
EP1121133A1 (fr) 1998-10-15 2001-08-08 Merck & Co., Inc. Methodes de stimulation de la formation osseuse
AU2183900A (en) * 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
GEP20043203B (en) 1999-12-22 2004-03-25 Pfizer Prod Inc EP4 Receptor Selective Agonists in the Treatment of Osteoporosis
BR0017157A (pt) 2000-03-17 2002-11-26 Alcon Inc Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
CN1366458A (zh) 2000-03-31 2002-08-28 东丽株式会社 毛发生长和毛发形成调节剂
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
OA12533A (en) 2000-11-27 2006-06-05 Pfizer Prod Inc Ep4 receptor selective agonists in the treatment of osteoporosis.
CA2434495A1 (fr) 2001-01-30 2002-08-08 Merck & Co., Inc. Compositions ophtalmiques pouvant traiter l'hypertension oculaire
WO2002077168A2 (fr) 2001-03-22 2002-10-03 Merck & Co., Inc. Souris deficientes en mch1r
WO2003047417A2 (fr) 2001-12-03 2003-06-12 Merck & Co., Inc. Agoniste du recepteur ep4, compositions et procedes associes
EP1461026A2 (fr) 2001-12-03 2004-09-29 Merck & Co., Inc. Methode de traitement de l'hypertension oculaire
US20050256117A1 (en) 2002-06-14 2005-11-17 Meng Hsin Chen Ophthalmic compositions for treating ocular hypertension
EP1515730A4 (fr) 2002-06-17 2005-07-20 Merck & Co Inc Nouveaux inhibiteurs de canaux maxi k, methodes d'utilisation et procede de fabrication associe
WO2003105724A2 (fr) 2002-06-17 2003-12-24 Merck & Co., Inc. Nouveaux bloqueurs de canaux maxi k, methodes d'utilisation et procedes de fabrication associes
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CA2511255C (fr) * 2003-01-10 2009-04-07 F. Hoffmann-La Roche Ag Derives de 2-piperidone agonistes de la prostaglandine
US6747037B1 (en) * 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs

Also Published As

Publication number Publication date
US20050227969A1 (en) 2005-10-13
ES2347434T3 (es) 2010-10-29
HRP20050845A2 (en) 2006-05-31
JP2006520758A (ja) 2006-09-14
EP1613621A1 (fr) 2006-01-11
BRPI0408690A (pt) 2006-03-28
JP4866992B2 (ja) 2012-02-01
US7053085B2 (en) 2006-05-30
WO2004085430A1 (fr) 2004-10-07
CA2519938C (fr) 2010-11-30
USRE42562E1 (en) 2011-07-19
US20110237511A1 (en) 2011-09-29
TW200427670A (en) 2004-12-16
NO20054951D0 (no) 2005-10-25
DE602004028229D1 (de) 2010-09-02
IS7999A (is) 2005-08-25
RU2005132930A (ru) 2006-02-10
WO2004085431A1 (fr) 2004-10-07
ECSP056037A (es) 2006-01-27
PE20050522A1 (es) 2005-07-06
CL2004000655A1 (es) 2005-01-21
MXPA05010189A (es) 2006-02-22
NO20054951L (no) 2005-12-22
AU2004224261A1 (en) 2004-10-07
AR040806A1 (es) 2005-04-20
CN1764659A (zh) 2006-04-26
EP1613621B1 (fr) 2010-07-21
CA2519938A1 (fr) 2004-10-07
US20040198701A1 (en) 2004-10-07
KR20060002873A (ko) 2006-01-09
ATE474837T1 (de) 2010-08-15
US7238710B2 (en) 2007-07-03

Similar Documents

Publication Publication Date Title
MA27667A1 (fr) Analogues de la prostaglandine comme antagonistes du recepteur de ep4
ES2252978T3 (es) Agonistas 5ht2 serotonergicos para tratar el glaucoma.
NO20071660L (no) Nye pyridinonderivater og deres anvendelse som positive allosteriske modulatorer av MGLUR2-reseptorer
AR055050A1 (es) Composicion farmaceutica que comprende n-etil-9a, 11a, 15s- trihidoxi-17-fenil-18,19,20-trinor-prosta -5z, 13e- dien-1-amida (bimatoprost) y cloruro de benzalconio, y uso de estos compuestos par la preparacion de la misma
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
TNSN01166A1 (fr) Composes agonistes selectifs des recepteurs ep4 et compositions les contenant.
AU2011282681B2 (en) Preservative free bimatoprost and timolol solutions
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA33365B1 (fr) Dérivés de spiro[2.4]heptane pontés utiles en tant qu'agonistes du récepteur de alx et/ou du récepteur fprl2
MA28435B1 (fr) Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4
MA29684B1 (fr) Composes de spiro-oxindole et utilisations associees en tant qu'agents therapeutiques
MA27428A1 (fr) Derives de pyrimidine et leur utilisation en tant que modulateurs cb2
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA31016B1 (fr) Composes de diazepan substitues comme antagonistes des recepteurs de l'orexine.
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
ATE464304T1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonist n
GEP20094780B (en) Prostaglandin nitrooxyderivatives
TN2009000028A1 (fr) Agonistes de ep2
EA200901160A1 (ru) Производные 3-циано-4-(4-тетрагидропиранфенил)пиридин-2-она
ATE336247T1 (de) Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
RU2017139870A (ru) Новые агонисты npr-b
DE60334905D1 (de) 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
MA30703B1 (fr) Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii.
MA28680B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.